annual cash & cash equivalents:
$315.35M-$70.84M(-18.34%)Summary
- As of today (May 23, 2025), AXSM annual cash & cash equivalents is $315.35 million, with the most recent change of -$70.84 million (-18.34%) on December 31, 2024.
- During the last 3 years, AXSM annual cash & cash equivalents has risen by +$228.88 million (+264.68%).
- AXSM annual cash & cash equivalents is now -18.34% below its all-time high of $386.19 million, reached on December 31, 2023.
Performance
AXSM Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$300.91M-$14.44M(-4.58%)Summary
- As of today (May 23, 2025), AXSM quarterly cash & cash equivalents is $300.91 million, with the most recent change of -$14.44 million (-4.58%) on March 31, 2025.
- Over the past year, AXSM quarterly cash & cash equivalents has dropped by -$30.53 million (-9.21%).
- AXSM quarterly cash & cash equivalents is now -31.16% below its all-time high of $437.11 million, reached on June 30, 2023.
Performance
AXSM quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AXSM Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.3% | -9.2% |
| 3 y3 years | +264.7% | +255.2% |
| 5 y5 years | +43.4% | +52.5% |
AXSM Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -18.3% | +264.7% | -31.2% | +310.0% |
| 5 y | 5-year | -18.3% | +264.7% | -31.2% | +310.0% |
| alltime | all time | -18.3% | >+9999.0% | -31.2% | >+9999.0% |
AXSM Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $300.91M(-4.6%) |
| Dec 2024 | $315.35M(-18.3%) | $315.35M(-3.7%) |
| Sep 2024 | - | $327.34M(+3.7%) |
| Jun 2024 | - | $315.66M(-4.8%) |
| Mar 2024 | - | $331.44M(-14.2%) |
| Dec 2023 | $386.19M(+92.3%) | $386.19M(-7.3%) |
| Sep 2023 | - | $416.56M(-4.7%) |
| Jun 2023 | - | $437.11M(+77.3%) |
| Mar 2023 | - | $246.51M(+22.7%) |
| Dec 2022 | $200.84M(+132.3%) | $200.84M(-11.7%) |
| Sep 2022 | - | $227.52M(+210.0%) |
| Jun 2022 | - | $73.39M(-13.4%) |
| Mar 2022 | - | $84.71M(-2.0%) |
| Dec 2021 | $86.47M(-53.0%) | $86.47M(-24.6%) |
| Sep 2021 | - | $114.62M(-18.8%) |
| Jun 2021 | - | $141.22M(-14.2%) |
| Mar 2021 | - | $164.66M(-10.5%) |
| Dec 2020 | $183.88M(-16.4%) | $183.88M(-9.1%) |
| Sep 2020 | - | $202.36M(+6.1%) |
| Jun 2020 | - | $190.68M(-3.4%) |
| Mar 2020 | - | $197.31M(-10.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2019 | $219.97M(+1474.7%) | $219.97M(+404.0%) |
| Sep 2019 | - | $43.64M(-18.8%) |
| Jun 2019 | - | $53.75M(+26.1%) |
| Mar 2019 | - | $42.62M(+205.1%) |
| Dec 2018 | $13.97M(-58.9%) | $13.97M(-8.2%) |
| Sep 2018 | - | $15.22M(-25.2%) |
| Jun 2018 | - | $20.35M(-23.6%) |
| Mar 2018 | - | $26.63M(-21.7%) |
| Dec 2017 | $34.02M(-7.1%) | $34.02M(+7.4%) |
| Sep 2017 | - | $31.67M(-16.6%) |
| Jun 2017 | - | $37.99M(-15.6%) |
| Mar 2017 | - | $45.02M(+22.9%) |
| Dec 2016 | $36.62M(-23.8%) | $36.62M(+8.1%) |
| Sep 2016 | - | $33.89M(-12.6%) |
| Jun 2016 | - | $38.75M(-12.1%) |
| Mar 2016 | - | $44.08M(-8.2%) |
| Dec 2015 | $48.04M(+1735.0%) | $48.04M(+939.5%) |
| Sep 2015 | - | $4.62M(-28.0%) |
| Jun 2015 | - | $6.41M(+145.0%) |
| Dec 2014 | $2.62M(+25.4%) | $2.62M |
| Dec 2013 | $2.09M | - |
FAQ
- What is Axsome Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Axsome Therapeutics?
- What is Axsome Therapeutics annual cash & cash equivalents year-on-year change?
- What is Axsome Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Axsome Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AXSM is $315.35M
What is the all time high annual cash & cash equivalents for Axsome Therapeutics?
Axsome Therapeutics all-time high annual cash & cash equivalents is $386.19M
What is Axsome Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AXSM annual cash & cash equivalents has changed by -$70.84M (-18.34%)
What is Axsome Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AXSM is $300.91M
What is the all time high quarterly cash & cash equivalents for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly cash & cash equivalents is $437.11M
What is Axsome Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, AXSM quarterly cash & cash equivalents has changed by -$30.53M (-9.21%)